Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken. Watch this short video to learn why!

FDA’s Class II Classification of Muscular Dystrophy Newborn Screening Test

$9.99

Gain in-depth insights into the FDA’s decision to classify the muscular dystrophy newborn screening test into class II, focusing on the implications for safety, effectiveness, and regulatory compliance. Learn about the special controls required and how this classification can streamline the regulatory process, ensuring innovative devices reach patients faster.

In this course you will learn the following:
* Understand the classification process and criteria for the muscular dystrophy newborn screening test.
* Identify the special controls and general controls applicable to the device.
* Recognize the impact of this classification on regulatory burdens and patient access to innovative devices.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year.  At the end of the one year term, the course will be set to “inactive”. 

Why This Course is Important
Without this course, you may miss crucial updates on regulatory changes affecting newborn screening tests, potentially impacting compliance and patient access to innovative technologies.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test.

Key regulatory references include:

Course SKU
FR-25-1404-1